- Home
- NISN vs EQ Comparison
NISN vs EQ Comparison
Compare NISN & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NISN
- EQ
- Stock Information
- Founded
- NISN 2005
- EQ 2017
- Country
- NISN China
- EQ United States
- Employees
- NISN N/A
- EQ N/A
- Industry
- NISN Metal Fabrications
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- NISN Industrials
- EQ Health Care
- Exchange
- NISN Nasdaq
- EQ Nasdaq
- Market Cap
- NISN 46.0M
- EQ 39.0M
- IPO Year
- NISN 2016
- EQ 2018
- Fundamental
- Price
- NISN $7.98
- EQ $0.69
- Analyst Decision
- NISN
- EQ Buy
- Analyst Count
- NISN 0
- EQ 2
- Target Price
- NISN N/A
- EQ $5.00
- AVG Volume (30 Days)
- NISN 120.8K
- EQ 311.2K
- Earning Date
- NISN 10-15-2024
- EQ 11-13-2024
- Dividend Yield
- NISN N/A
- EQ N/A
- EPS Growth
- NISN 12.54
- EQ N/A
- EPS
- NISN 4.19
- EQ N/A
- Revenue
- NISN $452,263,984.00
- EQ $42,623,000.00
- Revenue This Year
- NISN N/A
- EQ N/A
- Revenue Next Year
- NISN N/A
- EQ N/A
- P/E Ratio
- NISN $2.05
- EQ N/A
- Revenue Growth
- NISN 86.06
- EQ 26.25
- 52 Week Low
- NISN $2.50
- EQ $0.48
- 52 Week High
- NISN $22.55
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- NISN 36.75
- EQ 41.51
- Support Level
- NISN $9.55
- EQ $0.68
- Resistance Level
- NISN $11.31
- EQ $0.89
- Average True Range (ATR)
- NISN 1.18
- EQ 0.11
- MACD
- NISN 0.01
- EQ -0.03
- Stochastic Oscillator
- NISN 10.96
- EQ 12.17
About NISN NiSun International Enterprise Development Group Co. Ltd.
NiSun International Enterprise Development Group Co Ltd is a provider of supply chain solutions and integrated financial services. Nisun is dedicated to providing professional supply chain solutions to Chinese and foreign enterprises and financial institutions. Through its subsidiaries, it is engaged in delivering supply chain solutions, and supply chain trading services to its customers across different industries. The company also provides financial solutions to small and mid-sized enterprises within the supply chain ecosystem. Using its fintech platforms, it provides various financing options, including supply chain financing, trade financing, and receivables financing. Geographically, its operations are predominantly focused on markets within the People's Republic of China.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.